UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Clinical infectious diseases, 2020-09, Vol.71 (6), p.1379-1389

2020

Volltextzugriff (PDF)

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

The New England journal of medicine, 2020-11, Vol.383 (19), p.1827-1837

2020

Volltextzugriff (PDF)

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

JAMA : the journal of the American Medical Association, 2020-09, Vol.324 (11), p.1048

2020

Volltextzugriff (PDF)

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes

The Journal of infectious diseases, 2018-10, Vol.218 (11), p.1722-1729

2018

Volltextzugriff (PDF)

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

The New England journal of medicine, 2022-05, Vol.386 (19), p.1793-1803

2022

Volltextzugriff (PDF)

Gender Parity in Clinical PrEP Trials

The New England journal of medicine, 2019-12, Vol.381 (26), p.2585

2019

Volltextzugriff (PDF)

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Clinical infectious diseases, 2021-07, Vol.73 (2), p.e485-e493

2021

Volltextzugriff (PDF)

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Gastroenterology (New York, N.Y. 1943), 2015-11, Vol.149 (6), p.1462-1470

2015

Volltextzugriff (PDF)

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Clinical infectious diseases, 2021-12, Vol.73 (11), p.e4166-e4174

2021

Volltextzugriff (PDF)

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection

Gastroenterology (New York, N.Y. 1943), 2018-06, Vol.154 (8), p.2111-2121.e8

2018

Volltextzugriff (PDF)

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

Antimicrobial agents and chemotherapy, 2016-09, Vol.60 (9), p.5368-5378

2016

Volltextzugriff (PDF)

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

JAMA : the journal of the American Medical Association, 2014-07, Vol.312 (4), p.353

2014

Volltextzugriff (PDF)

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Clinical infectious diseases, 2016-12, Vol.63 (11), p.1405-1411

2016

Volltextzugriff (PDF)

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

Gastroenterology (New York, N.Y. 1943), 2016-09, Vol.151 (3), p.501-512.e1

2016

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Clinical pharmacokinetics, 2016-11, Vol.55 (11), p.1337-1351

2016

Volltextzugriff (PDF)

Compassionate Use of Remdesivir in Children With Severe COVID-19

Pediatrics (Evanston), 2021-05, Vol.147 (5), p.1

2021

Volltextzugriff (PDF)

Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Clinical pharmacokinetics, 2018-11, Vol.57 (11), p.1369-1383

2018

Volltextzugriff (PDF)

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Gastroenterology (New York, N.Y. 1943), 2017-07, Vol.153 (1), p.113-122

2017

Volltextzugriff (PDF)

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Clinical infectious diseases, 2021-06, Vol.72 (11), p.e815-e824

2021

Volltextzugriff (PDF)

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Gastroenterology (New York, N.Y. 1943), 2015, Vol.148 (1), p.108-117

2015

Volltextzugriff (PDF)

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

Antimicrobial Agents and Chemotherapy, 2013-12, Vol.57 (12), p.6333-6340

2013

Volltextzugriff (PDF)

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

Science translational medicine, 2021-06, Vol.13 (599)

2021

Volltextzugriff (PDF)

1 – 25 von 182

Suche als RSS-Feed

Aktive Filter

ThemaHepatitis C

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(176)
Mit Volltextzugriff
(158)

Publikationsform

Artikel
(181)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(97)
Life Sciences & Biomedicine
(96)
Humans
(72)
Female
(49)
Male
(45)
Middle Aged
(41)
Gastroenterology And Hepatology
(36)
Infectious Diseases
(36)
Adult
(33)
Antiviral Agents - Therapeutic Use
(33)
Hepacivirus - Genetics
(31)
Genotype
(27)
Gastroenterology & Hepatology
(26)
Treatment Outcome
(25)
Aged
(24)
Hepatitis C, Chronic - Drug Therapy
(24)
Microbiology
(22)
Pharmacology & Pharmacy
(22)
Drug Therapy, Combination
(20)
Immunology
(19)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection

Gender Parity in Clinical PrEP Trials

Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection

Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein

Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials

Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir

Clinical Pharmacokinetics and Pharmacodynamics of Ledipasvir/Sofosbuvir, a Fixed-Dose Combination Tablet for the Treatment of Hepatitis C

Compassionate Use of Remdesivir in Children With Severe COVID-19

Drug–Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir In Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy

Aktive Filter

Suchergebnisse filtern